The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure
Abstract
Background —Although previous studies suggested that TNF may contribute to heart failure progression, it is unclear whether antagonizing TNF is beneficial in heart failure patients. Methods and Results —Eighteen NYHA class III heart failure patients were randomized into a double-blind dose-escalation study to examine the safety and potential efficacy of etanercept, a specific TNF antagonist (Enbrel). Patients received placebo (6 patients) or an escalating dose (1, 4, or 10 mg/m 2 ) of etanercept (12 patients) given as a single intravenous infusion. Safety parameters and patient functional status were assessed at baseline and at days 1, 2, 7, and 14. There were no significant side effects or clinically significant changes in laboratory indices. There was, however, a decrease in TNF bioactivity and a significant overall increase in quality-of-life scores, 6-minute walk distance, and ejection fraction in the cohort that received 4 or 10 mg/m 2 of etanercept; there was no significant change in these parameters in the placebo group. Conclusions —A single intravenous infusion of etanercept was safe and well tolerated in patients with NYHA class III heart failure. These studies provide provisional evidence that suggests that etanercept is sufficient to lower levels of biologically active TNF and may lead to improvement in the functional status of patients with heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Self-citationTorre-Amione, G., Kapadia, S., Benedict, C., Oral, H., Young, J. B., & Mann, D. L. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00589-7 · Cited by 1,211
Self-citationKubota, T., McTiernan, C. F., Frye, C. S., Slawson, S. E., Lemster, B. H., Koretsky, A. P., Demetris, A. J., & Feldman, A. M. (1997) · Circulation Research · doi:10.1161/01.res.81.4.627 · Cited by 829
Bozkurt, B., Kribbs, S. B., Clubb, F. J., Michael, L. H., Didenko, V. V., Hornsby, P. J., Seta, Y., Oral, H., Spinale, F. G., & Mann, D. L. (1998) · Circulation · doi:10.1161/01.cir.97.14.1382 · Cited by 821
Self-citationBasic mechanisms in heart failure: The cytokine hypothesis
Seta, Y., Shan, K., Bozkurt, B., Oral, H., & Mann, D. L. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80047-9 · Cited by 444
Self-citationSliwa, K., Skudicky, D., Candy, G., Wisenbaugh, T., & Sareli, P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09338-0 · Cited by 216
Cited by
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Self-citationInflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future
Mann, D. L. (2002) · Circulation Research · doi:10.1161/01.res.0000043825.01705.1b · Cited by 988
Self-citationSchleithoff, S. S., Zittermann, A., Tenderich, G., Berthold, H. K., Stehle, P., & Koerfer, R. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.754 · Cited by 925
Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure
Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., Niebauer, J., Hooper, J., Volk, H.-D., Coats, A. J. S., et al. (2000) · Circulation · doi:10.1161/01.cir.102.25.3060 · Cited by 810
Chronic Heart Failure and Inflammation: What Do We Really Know?
Dick, S. A., & Epelman, S. (2016) · Circulation Research · doi:10.1161/circresaha.116.308030 · Cited by 692
Development of anti-TNF therapy for rheumatoid arthritis
Feldmann, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri802 · Cited by 673
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038010 · Cited by 658
Inflammatory mediators in chronic heart failure: an overview
Anker, S. D., & von Haehling, S. (2004) · Heart · doi:10.1136/hrt.2002.007005 · Cited by 627
“Etanercept is a TNFR-2 fusion protein, which binds to TNFα and functionally inactivates this cytokine. A small double blind, placebo controlled pilot study in 18 patients with moderate heart failure showed promising results.”
BackgroundAnti-inflammatory effects of exercise: role in diabetes and cardiovascular disease
Pedersen, B. K. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12781 · Cited by 617
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00008 · Cited by 455
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Congestive Heart Failure: Fifty Years of Progress
Braunwald, E., & Bristow, M. R. (2000) · Circulation · doi:10.1161/01.cir.102.suppl_4.iv-14 · Cited by 437
Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure
Hanna, A., & Frangogiannis, N. G. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07071-0 · Cited by 418
TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure
Kleinbongard, P., Heusch, G., & Schulz, R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.002 · Cited by 409
Bozkurt, B., Torre-Amione, G., Warren, M. S., Whitmore, J., Soran, O. Z., Feldman, A. M., & Mann, D. L. (2001) · Circulation · doi:10.1161/01.cir.103.8.1044 · Cited by 388
Self-citationAnker, S. D., & Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00470-9 · Cited by 367
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Inflammatory Cytokines in Heart Failure: Mediators and Markers
Gullestad, L., Ueland, T., Vinge, L. E., Finsen, A., Yndestad, A., & Aukrust, P. (2012) · Cardiology · doi:10.1159/000338166 · Cited by 350
Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure
Gullestad, L., Aass, H., Fjeld, J. G., Wikeby, L., Andreassen, A. K., Ihlen, H., Simonsen, S., Kjekshus, J., Nitter-Hauge, S., Ueland, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.2.220 · Cited by 349
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Systemic inflammation in heart failure – The whys and wherefores
Yndestad, A., Kristian Damås, J., Øie, E., Ueland, T., Gullestad, L., & Aukrust, P. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9196-2 · Cited by 294
The syndrome of cardiac cachexia
Anker, S. D., & Sharma, R. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00233-4 · Cited by 293
Importance of Kupffer Cells for T-Cell-Dependent Liver Injury in Mice
Schümann, J., Wolf, D., Pahl, A., Brune, K., Papadopoulos, T., van Rooijen, N., & Tiegs, G. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64804-3 · Cited by 284
Olsson, L. G., Swedberg, K., Clark, A. L., Witte, K. K., & Cleland, J. G. F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi162 · Cited by 284
Role of Inflammation in Heart Failure
Shirazi, L. F., Bissett, J., Romeo, F., & Mehta, J. L. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0660-3 · Cited by 278
Ohtsuka, T., Hamada, M., Hiasa, G., Sasaki, O., Suzuki, M., Hara, Y., Shigematsu, Y., & Hiwada, K. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01121-9 · Cited by 253
Elsässer, A., Suzuki, K., & Schaper, J. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1125 · Cited by 138
Inflammation and chronic heart failure–potential therapeutic role of intravenous immunoglobulin
Aukrust, P., Yndestad, A., Damås, J. K., & Gullestad, L. (2004) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00103-4 · Cited by 37
The role of inflammation in the pathogenesis of heart failure
Lisman, K. A., Stetson, S. J., Koerner, M. M., Farmer, J. A., & Torre-Amione, G. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0051-3 · Cited by 18
Metadata
- Authors
- Deswal, A., Bozkurt, B., Seta, Y., Parilti-Eiswirth, S., Hayes, F. A., Blosch, C., & Mann, D. L.
- Venue
- Circulation
- Published
- 1999-06-29
- Volume
- 99
- Issue
- 25
- Pages
- 3224-3226
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2008787181
- Cited by
- 393
- References
- 6
- FWCI
- 36.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.